B. Chanu

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Marianne Abifadel, Mathilde Varret, Jean‐Pierre Rabès et al. · Nature Genetics · 2003 · 3K citations

Life Sciences, Genetics, Molecular Genetics +10

Characterization of Autosomal Dominant Hypercholesterolemia Caused by <i>PCSK9</i> Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody

Paul N. Hopkins, Joep C. Defesche, Sigrid W. Fouchier et al. · Circulation Cardiovascular Genetics · 2015 · 110 citations · Full text

Life Sciences, Genetics, Pharmacotherapy +17

Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study

Paul Valensi, A. Avignon, Ariane Sultan et al. · Cardiovascular Diabetology · 2016 · 76 citations · Full text

Medicine, Cardiology, Internal Medicine +17

Efficacy and tolerability profile of nebivolol vs atenolol in mild‐to‐moderate essential hypertension: Results of a double‐blind randomized multicentre trial

Fosca Quarti Trevano, A. Facchini, Torakis Toutouzas et al. · Blood Pressure · 2003 · 55 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Cardiovascular Risk Prediction Is Improved by Adding Asymptomatic Coronary Status to Routine Risk Assessment in Type 2 Diabetic Patients

Emmanuel Cosson, Minh Tuan Nguyen, B. Chanu et al. · Diabetes Care · 2011 · 52 citations · Full text

Medicine, Cardiology, Nuclear Medicine +17